35 IU/mL 208 46 22.1 16.7–28.4 (2a) Transgression from <0.2 to >0.7 IU/mL 421 15 3.6 2.0–5.8 (2b) Regression from >0.7 to <0.2 IU/mL 153 8 5.2 5.3–10.0 (3a) As defined in (1a) plus increase ≥0.35 IU/mL 462 41 8.9 6.4–11.8 (3b) As defined in (1b) plus decrease ≥0.35 IU/mL 208 33 15.9 11.2–21.6 (4a) As defined in (1a) plus increase ≥0.50 IU/mL 462 31 selleck chemicals llc 6.7 4.6–9.4 (4b) As defined in (1b) plus decrease ≥0.50 IU/mL 208 21 10.1 6.4–15.0 TST  (5a) First TST <10 mm, increase ≥10 mm 199 61 30.7 24.3–37.6  (5b) First TST ≥10 mm, decrease ≥10 mm 188 4 2.1 0.6–5.4

 (6a) TST <10 mm, increase ≥6 mm 199 98 49.2 42.1–56.4  (6b) TST ≥10 mm, decrease ≥6 mm 188 7 3.8 1.5–7.5 Source population: Those who fulfilled the first condition (positive or Staurosporine negative first test) of the different definitions for conversion and reversion N absolute number of converted or reverted HCWs % annual rate of reversions and conversions 95% CI 95% confidence interval In the subgroup with three consecutive QFTs, the same trend was see more observed (Table 5) as in the whole study group. However, the proportion of those who were positive throughout all three QFTs dropped to 14.3% (36/252) from 24.2% (162/670) with two positive consecutive QFTs in the whole group. Two (10%) reversions (one transient reversion—second

QFT negative and third QFT positive) were observed in those with a baseline INF-γ concentration ≥3.0 IU/mL, while 73.3% showed a reversion at the second (n = 10) or the third (n = 1) QFT when the baseline INF-γ concentration was ≥0.35 to <0.7 IU/mL. In addition, one (6.7%) transient cAMP reversion occurred. In Figs. 1 and 2, the association between baseline INF-γ concentration and reversion or conversion can also be seen. The median of the baseline INF-γ concentration

was ≥0.1 IU/mL in those with conversion in the second or in the third QFT (Fig. 1). Only one reversion occurred when the baseline INF-γ concentration was above 3.0 IU/mL (see asterisk in Fig. 2). Table 5 Results of second and third QFT depending on INF-γ concentration in first QFT 1st QFT (IU/mL) 2nd and 3rd QFT Total −− ++ +− −+ N (%) N (%) N (%) N (%) N (%) <0.1 139 4 5 7 155 89.7 2.6 3.2 4.5 78.7 0.1 ≤ 0.2 12 4 2 3 21 57.1 19.0 9.5 14.3 10.7 0.2 ≤ 0.35 7 6 5 3 21 33.3 28.6 23.8 14.3 10.7 Neg. 1st QFT 158 14 12 13 197 80.2 7.1 6.1 6.6 100.0 (78.2) 0.35 ≤ 0.7 10 3 1 1 15 66.6 20.0 6.7 6.7 27.3 0.7-1.0 1 4 1 0 6 16.7 66.7 16.7 – 10.9 >1–3 2 11 1 0 14 14.3 78.6 7.1 – 25.5 >3 1 18 0 1 20 5.0 90.0 – 5.0 36.4 Pos. 1st QFT 14 36 3 2 55 25.5 65.5 5.5 3.6 100.0 (21.8) All 172 50 15 15 252 68.3 19.8 6.0 6.0 100.0 Fig. 1 Box plot for INF-γ concentration of the first QFT depending on whether all three consecutive QFTs were negative (− − −), the third QFT became positive (− − +), only the second QFT was positive (− + −) or the two following QFT were positive (− + +) for the subgroup with a negative first QFT (n = 197) Fig.